Medartis Holding AG (SIX: MED) announced that its shareholders approved all substantive proposals of the Board of Directors with significant majorities exceeding 90.9% at the Annual General Meeting (AGM) held on April 23, 2026. The meeting saw strong participation, with 77.4% of total share capital represented.
Seven members of the Board of Directors standing for re-election received resounding endorsement, each securing more than 93.8% support from represented votes. Yang Xu was newly elected to the Board of Directors with 99.7% endorsement and will join the Finance and Audit Committee. Chairman Marco Gadola continues to lead the board. Jennifer Dean decided not to stand for re-election after two years with Medartis. The assembly also confirmed Damien Tappy and Marco Gadola as members of the Human Resources and Compensation Committee (HRCC), ensuring continuity in oversight of human capital strategy.
Shareholders granted discharge to board members for their governance during the 2025 term and approved the proposed maximum total remuneration for both the Board of Directors and the Executive Management Board. The 2025 management report and annual financial statements received nearly unanimous approval (99.99%), while the remuneration report was approved by 91.0% in a consultative vote. Additionally, the sustainability report gained strong endorsement (99.2%) of represented shares, confirming Medartis' commitment to transparent ESG practices.
In accordance with the board's proposal, shareholders confirmed the re-election of Neovius AG as independent voting representative and Ernst & Young AG as statutory auditors. For a detailed listing of all resolutions at the 2026 Annual General Meeting, please visit this link.
Medartis also confirmed upcoming dates for its investor and corporate calendar. On 4 June 2026, Medartis will host an investor event in Basel, held on the fringes of the FESSH Hand Surgery Congress. The event is open to institutional investors and will provide an opportunity to engage with the company's management. The first-half 2026 results will be published on 18 August 2026, followed by the customary analyst and media briefing. The next Annual General Meeting is scheduled for 22 April 2027 at the company's headquarters in Basel.
As of today’s Annual General Meeting, the Medartis Board of Directors consists of Marco Gadola (Chairman), Dr. h.c. Thomas Straumann (Vice Chairman), Willi Miesch, Damien Tappy, Nadia Tarolli Schmidt, Ciro Roemer, Martha Shadan, and Yang Xu.
